Narendranath Epperla MD MS, FACP

Oncology•Salt Lake City, UT

Hematologic Oncology

Associate Professor

Join to View Full Profile

2000 Circle of HopeSalt Lake City, UT 84112

Summary

Dr. Narendranath Epperla is an Associate Professor and Associate Chief of Clinical Research at Huntsman Cancer Institute, University of Utah.

Education & Training

Medical College of WisconsinMS, 2015 - 2017
Medical College of Wisconsin Affiliated HospitalsFellowship, Hematology and Medical Oncology, 2014 - 2017
Marshfield ClinicResidency, Internal Medicine, 2010 - 2013
Kamineni Institute of Medical ScienceClass of 2007

Certifications & Licensure

UT State Medical License 2024 - 2026
OH State Medical License 2017 - 2025
WI State Medical License 2011 - 2017
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma Start of enrollment: 2021 May 24
RECRUITING
PHASE1
Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Start of enrollment: 2022 Jul 01
Withdrawn
Phase 1
Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma Start of enrollment: 2018 Sep 26
ACTIVE_NOT_RECRUITING
NA
A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma Start of enrollment: 2023 Jan 26
RECRUITING
PHASE1, PHASE2
Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma Start of enrollment: 2021 Apr 29
ACTIVE_NOT_RECRUITING
PHASE1
Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma Start of enrollment: 2023 May 10
RECRUITING
Pirtobrutinib in Combination With Rituximab in Newly Diagnosed Marginal Zone Lymphoma (R+Pirto in Newly Diagnosed MZL) Start of enrollment: 2025 Jan 28
RECRUITING
PHASE2
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas Start of enrollment: 2025 Feb 04
RECRUITING
PHASE2
Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery (SRS) in Patients With Primary and Secondary Central Nervous System Lymphomas (Lonca-R After SRS in CNSL) Start of enrollment: 2025 Mar 06
RECRUITING
PHASE1
Loncastuximab Tesirine and Rituximab as Bridging Therapy Prior to Standard-of-care CD19 CAR T-cell Therapy in Patients With Large B-cell Lymphoma
NOT_YET_RECRUITING
PHASE2
Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphomas
NOT_YET_RECRUITING
PHASE1
Join now to see all

Publications & Presentations

PubMed

Differences in Observed Outcomes and Toxicities for Adolescent and Young Adult Patients With Aggressive Mature B-Cell Lymphomas Treated at an Adult Versus Pediatric Ca...
Allison M LeHanka, Ann M Kebede, Neda Amirmokhtari, Joseph R Stanek, Faye Willen
Pediatric Blood & Cancer. 2025-06-01
Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort Study.
Pallawi Torka, Natalie S Grover, Timothy J Voorhees, Reem Karmali, Kaitlin Annunzio
Hematological Oncology. 2025-05-01
Association of CAR-T approval on outcomes in patients with diffuse large B-cell lymphoma at the population level in the United States.
John L Vaughn, Angela Ramdhanny, Malak Munir, Sravani Rimmalapudi, Narendranath Epperla
Biomarker Research. 2025-04-24

Abstracts/Posters

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of...
Narendranath Epperla, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...
Narendranath Epperla, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
Narendranath Epperla, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma
Narendranath Epperla, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant
Narendranath Epperla, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)
Narendranath Epperla, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
Narendranath Epperla, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Authored Content

Incorporating Novel Agents Into Classical Hodgkin Lymphoma TreatmentDecember 2021

Press Mentions

Incorporating Novel Agents into Classical Hodgkin Lymphoma TreatmentDecember 1st, 2021
Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-cell LymphomaFebruary 8th, 2021